4:08 AM
 | 
Feb 28, 2019
 |  BC Extra  |  Financial News

Third Rock launches Maze with $191M to target genetic modifiers

Maze Therapeutics (San Francisco, Calif.) launched Thursday with $191 million to develop treatments targeting genetic modifiers. The company is combining large-scale human genetics and functional genomics to analyze...

Read the full 118 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >